# US 2012/0252094 A1 · Recombinant Butyrylcholinesterases and Truncates Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252094 A1
- Document ID: US20120252094A1
- Status: Published application
- Kind: A1
- Application number: 13/517,081
- Filed: 2010-12-21
- Published: 2012-10-04
- Earliest claimed: 2009-12-21
- Assignees: PharmAthene, Inc.
- Inventors: Kalvin Yim; Steven Danso; Edward Hausknecht
- Web page: https://patentgrep.com/patent/US20120252094A1

## CPC

- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 9/18: Carboxylic ester hydrolases {(3.1.1)}
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H 21/02: with ribosyl as saccharide radical
- C07H 21/04: with deoxyribosyl as saccharide radical
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- C07K 2319/35: containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/66: General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Isolated nucleic acids encoding polypeptides that exhibit butyrylcholinesterase (BChE) enzyme activity are disclosed, along with molecular criteria for preparing such nucleic acids, including codon optimization. Methods of preparing modified and/or truncated BChE molecules having selected properties, especially selective formation of monomers, are also described. Vectors and cells containing and/or expressing the nucleic acids are also disclosed.

## Claims

### Claim 1

An isolated nucleic acid that encodes a polypeptide having BChE enzyme activity, wherein the percentage of guanine plus cytosine (G+C) nucleotides in the coding region of said nucleic acid is greater than 40% but not greater than 80%.

### Claim 2 (depends on 1)

The isolated nucleic acid of claim 1, wherein the percentage of guanine plus cytosine (G+C) nucleotides in the coding region of said nucleic acid is greater than 45% but not greater than 80%.

### Claim 3 (depends on 1)

The isolated nucleic acid of claim 1, wherein the percentage of guanine plus cytosine (G+C) nucleotides in the coding region of said nucleic acid is greater than 50% but not greater than 80%.

### Claim 4 (depends on 1)

The isolated nucleic acid of claim 1, wherein the percentage of guanine plus cytosine (G+C) nucleotides in the coding region of said nucleic acid is greater than 55% but not greater than 80%.

### Claim 5 (depends on 1)

The isolated nucleic acid of claim 1, wherein the percentage of guanine plus cytosine (G+C) nucleotides in the coding region of said nucleic acid is greater than 60% but not greater than 80%.

### Claim 6 (depends on 1)

The isolated nucleic acid of claim 1, wherein the percentage of guanine plus cytosine (G+C) nucleotides in the coding region of said nucleic acid is at least 60% but not greater than 80%.

### Claim 7 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid does not contain or encode an internal TATA-box.

### Claim 8 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid encodes one or more sialylation sites on said polypeptide.

### Claim 9 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid does not contain or encode an internal ribosomal entry site.

### Claim 10 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid does not contain or encode a splice donor or acceptor site.

### Claim 11 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid contains or encodes at least one Kozak sequence upstream of the start site.

### Claim 12 (depends on 1)

The isolated nucleic acid of claim 1, wherein the sequence of said nucleic acid has a Codon Adaptation Index (CAI) of at least 0.7.

### Claim 13 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid has a CAI of at least 0.8.

### Claim 14 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid has a CAI of at least 0.9.

### Claim 15 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid has a CAI of at least 0.97.

### Claim 16 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid comprises a nucleotide sequence having at least 90% identity to the nucleotide sequence of SEQ ID NO: 1 or the complement thereof.

### Claim 17 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid comprises a nucleotide sequence having at least 95% identity to the nucleotide sequence of SEQ ID NO: 1 or the complement thereof.

### Claim 18 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid comprises a nucleotide sequence having at least 98% identity to the nucleotide sequence of SEQ ID NO: 1 or the complement thereof.

### Claim 19 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid comprises the nucleotide sequence of SEQ ID NO: 1 or the complement thereof.

### Claim 20 (depends on 1)

The isolated nucleic acid of claim 1, wherein said BChE polypeptide comprises amino acids 22 to 564 of SEQ ID NO: 2.

### Claim 21 (depends on 1)

The isolated nucleic acid of claim 1, wherein said BChE polypeptide contains fewer than the number of amino acids in SEQ ID NO: 2.

### Claim 22 (depends on 1)

The isolated nucleic acid of claim 1, wherein said BChE polypeptide forms only monomers.

### Claim 23 (depends on 1)

The isolated nucleic acid of claim 1, wherein said BChE is missing all or a portion of the WAT domain.

### Claim 24 (depends on 1)

An isolated fragment of the nucleic acid of claim 1, wherein said fragment encodes a polypeptide having BChE enzyme activity.

### Claim 25 (depends on 1)

A vector comprising a nucleic acid of claim 1.

### Claim 26 (depends on 25)

A recombinant cell containing the vector of claim 25.

### Claim 27 (depends on 26)

A method of preparing a polypeptide having BChE enzyme activity, comprising expressing said polypeptide from the cell of claim 26.

### Claim 28 (depends on 26)

The recombinant cell of claim 26, wherein said cell is a mammalian cell.

### Claim 29 (depends on 26)

The recombinant cell of claim 26, wherein said cell is a human cell.

### Claim 30 (depends on 26)

The recombinant cell of claim 26, wherein said cell is a Per.C6 cell.

### Claim 31 (depends on 27)

The method of claim 27, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

### Claim 32 (depends on 27)

The method of claim 27, wherein said polypeptide forms only monomers.

### Claim 33 (depends on 27)

The method of claim 27, wherein said polypeptide does not contain all or a portion of the WAT domain.

### Claim 34 (depends on 33)

The method of claim 33, wherein said polypeptide does not contain the WAT domain.

### Claim 35 (depends on 27)

The method of claim 27, wherein said polypeptide does not contain all or a portion of the amino acid sequence of SEQ ID NO: 7.

### Claim 36 (depends on 27)

The method of claim 27, wherein said polypeptide comprises amino acids 22-564 of SEQ ID NO: 2.

### Claim 37 (depends on 27)

The method of claim 27, wherein said polypeptide consists of amino acids 22-564 of SEQ ID NO: 2.

### Claim 38 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid is a DNA or the complement thereof.

### Claim 39 (depends on 38)

The isolated nucleic acid of claim 38, wherein said DNA is a cDNA or the complement thereof.

### Claim 40 (depends on 1)

The isolated nucleic acid of claim 1, wherein said nucleic acid is an RNA.
